A case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period

Edwards, Ella P., Gray, Laurence A., Elamin, Muhammad E. M. O., Veiraiah, Aravindan, Thanacoody, Ruben H. K., Coulson, James M. · 2025 · Clinical Toxicology

AI-extracted · unverified · confirm at source

7 UK poison centre cases (2012-2022), 0 fatalities: 6/7 developed cardiotoxicity; 2 cardiac arrests with hypoxic brain injury (survivors); QTc 680-720 msec; no dose-response relationship; doses 5-34g root bark.

Dosing: Acute: 5–34 g root bark (where reported); chronic: 0.5–0.7 g root bark 5/7 days for 2 months (Patient 6); mixed preparations (root bark, ibogaine HCl tablets, capsules); dose unknown in majority of cases (oral)

Sample size: 7

Safety data present: QTC, ELECTROLYTE

Contraindications: Pre-existing cardiac conditions, Concurrent opioid use (methadone, buprenorphine), Co-ingestants (benzodiazepines, zopiclone, alimemazine), Unsupervised or unscreened settings, CYP2D6 poor metaboliser status (flagged as variable susceptibility factor, not assessed in any case)